Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha]

Exelixis, Inc. (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
Company Research Source: Seeking Alpha
Exelixis lower after IMspire170 fails to meet primary endpoint Exelixis (NASDAQ: EXEL -3% did not meet its primary endpoint IMspire170 showed the combination did not reduce the risk of disease progression or death compared to pembrolizumab, according to partner Roche ( OTCQX:RHHBY Cobimetinib is an Exelixis-discovered MEK inhibitor, and atezolizumab is an anti-PDL1 antibody discovered and developed by Roche's Genentech subsidiary. Show less Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for EXEL alerts
Opt-in for
EXEL alerts

from News Quantified
Opt-in for
EXEL alerts

from News Quantified